540 related articles for article (PubMed ID: 18297515)
1. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
3. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
4. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
5. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
7. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
8. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
9. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
Xu W; Li JY; Xia J; Zhang SJ; Fan L; Qiao C
Leuk Lymphoma; 2008 May; 49(5):955-8. PubMed ID: 18464114
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
11. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
12. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
13. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
14. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
15. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
[TBL] [Abstract][Full Text] [Related]
16. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Barbui T; Falanga A
Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
Zulkeflee RH; Zulkafli Z; Johan MF; Husin A; Islam MA; Hassan R
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300032
[TBL] [Abstract][Full Text] [Related]
18. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
19. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
[No Abstract] [Full Text] [Related]
[Next] [New Search]